No Complaints about shortage of stents even on my whatsapp number which is public and I Congratulate the Industry for ensuring smooth supplies”, Shri Bhupendra Singh, Chairman, NPPA, Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, Government of India.
Parenteral medicines are administered by routes other than the mouth or digestive system. The survey was titled Survey on the extent of problems with non-essential quality non-standard medicines in the country.
The Ministry of Health had asked the National Institute of Biological Sciences (NIB) to conduct the survey, in which a total of 47,954 samples were taken by drug inspectors from mid-2014 to mid-2016. A two-year national survey conducted under the supervision of the central government revealed that approximately 10% of government supply chain drugs are not of standard quality (NSQ).
However, the estimated percentage of NSQ drugs in the retail supply chain was only 3 per cent. State drug monitors served as nodal agents and coordinated the collection of samples and sent them to NIB.
Of the 47 954 samples taken, 98.03% were tested and analyzed in the laboratory. Of these 33,656 were retail outlets, 8,369 were from government sources and the rest of the samples came from ports. During analysis of samples declared NSQ from government supply chain, the following trend was observed: civil hospital stores: 11.03 per cent, state government medical store depots: 10.44 per cent, ESI (Employee State Insurance) dispensaries: 9.01 per cent, CGHS (Central Government Health Scheme) dispensaries: 4.11 per cent,” the survey noted.
“The estimated percentage of NSQ drugs from government sources in India was 10.02 per cent and for spurious drugs was 0.059 per cent.
“The fact that the NSQ (drugs) from government sources are 3.17 times higher than in the retail highlights that there is something amiss in the existing procurement processes, especially in states where the NSQ is much higher than the national average. Further, lack of uniform levels of enforcement may be leading to difference in the extent of NSQ in retail outlets and government supply chain in different States/UTs(union territories). The NSQs are much higher in case of parenterals as compared with oral dosage forms and this area therefore needs special attention,” the survey commented.
Understanding the gravity of the issue, the National Drug Survey recommended: "It is necessary for government procurement agencies to review their procurement guidelines with respect to manufacturers' qualification requirements. Should develop and implement risk-based pre-inspection standards for the selection of quality drug manufacturers and adopt quality testing of each shipment from NABL accredited laboratories (National Accreditation Board for Laboratories Testing and Calibration Laboratories ).
It further added that government warehouses, medical store depots and pharmacies should have adequate storage facilities and provision for temperature and humidity control, sufficient air conditioned space, refrigerators, deep freezers etc. along with their annual maintenance contracts.
Union Minister of State for External Affairs Gen VK Singh (ret) said that Indian missions abroad should promote alternative treatment methods such as Ayush and Ayurveda. "We have asked all our presidents and all our missions to make a serious effort to promote Ayush and Ayurveda," he said.
In 2009, about 5% of drugs on the market were substandard, while spurious drugs were twice as high as current levels. The incidence of substandard medicine in India has come down substantially in the last five years, findings of a latest study show.
The National Pharmaceutical Pricing Authority (NPPA) has begun scrutiny of such devices, even asking makers to log in every detail about their manufacture and cost. After cardiac stents, about 14 medical devices increasingly sold at inflated prices in hospitals could see price regulation in the months to come. The list includes orthopedic implants, intraocular lenses and artificial heart valves to consumables such as syringes, needles and catheters.
The prospect of a major change to the regulatory agency comes as drug makers are under fire for high prices, including Marathon Pharmaceuticals LLC, which said "stop" the launch of its drug Duchenne muscular dystrophy after American lawmakers questioned her $ 89,000 a year award.
The Union health ministry said it set tough targets to reduce infant and maternal mortality rates, which are already at a faster pace than the global rate.
Union Health Minister J P Nadda said for the first time that the ministry has made fighting diseases such as kalazar, measles and other targeted people. He said In terms of maternal and child health, I talked earlier that our rate of reduction of AMI, MMR and total fertility rate (TFR) is faster than the global rate .
For the first time in the budget, we focused on targeting diseases. We are committed to ensuring that the department is focused on results, targets and results. Only talk about this year, but until 2020-2025, he said.
They are very encouraging results. Now we have set up tough targets within ourselves (ministry). Under it, for IMR, till 2019, we will reduce it from 37 to 28. For MMR till 2020, we have set a target of reducing it from 167 to 100, the minister said.
Noting that stress has been given on non-communicable diseases (NCDs), Nadda said universal screening for hypertension, diabetes, cervical, breast and oral cancers will be started in 100 districts of the country this year.
There has been a significant increase of Rs 10,290 crore in the health budget (from last year). From Rs 37,061 crore it rose to 47,352 crore this year, which is a jump of 27, 77 percent, he said. There was a style of operation where the previous government used to present a budget and then reduce it. After arriving in the news, it was reduced, Nadda alleged.
Among the main concerns of the US pharmacy sector in India are the unpredictable IP environment, high tariffs and drug taxes, failure of regulatory data protection, access policies Discriminatory and non-transparent markets and the unpredictable environment for clinical research.
The National Pharmaceutical Pricing Authority (NPPA) made it mandatory for these facilities to disclose separately the cost of the stent when charging a patient. Medical facilities, including retailers and resellers of stents, should also display the price list of stents on a part of their premises that is easily accessible to anyone wishing to consult the same.
Do Not Forget to Verify
(Click on Subscription link in your inbox)
--------
Also Join: 
.png)
